1. Home
  2. PAVM vs SCYX Comparison

PAVM vs SCYX Comparison

Compare PAVM & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PAVmed Inc.

PAVM

PAVmed Inc.

N/A

Current Price

$2.80

Market Cap

41.1M

Sector

Health Care

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

N/A

Current Price

$4.18

Market Cap

44.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PAVM
SCYX
Founded
2014
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.1M
44.4M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
PAVM
SCYX
Price
$2.80
$4.18
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
★ $36.50
$36.33
AVG Volume (30 Days)
25.0K
★ 274.2K
Earning Date
11-12-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 61.36
EPS
N/A
★ N/A
Revenue
★ $3,000,000.00
$257,000.00
Revenue This Year
$132.39
N/A
Revenue Next Year
$263.64
$977.86
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 20.00
N/A
52 Week Low
$0.21
$0.57
52 Week High
$28.44
$6.09

Technical Indicators

Market Signals
Indicator
PAVM
SCYX
Relative Strength Index (RSI) 30.04 37.99
Support Level $0.21 $4.08
Resistance Level $6.56 $4.30
Average True Range (ATR) 0.33 0.45
MACD -0.06 -0.05
Stochastic Oscillator 12.00 4.70

Price Performance

Historical Comparison
PAVM
SCYX

About PAVM PAVmed Inc.

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: